Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Multi-Center, Open Label, 24-Month Treatment Study to Establish the Safety, Tolerability, Efficacy, Pharmacokinetics of Canakinumab (Anti-IL-1 Beta Antibody) in Patients With NOMID / CINCA Syndrome

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00770601
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:08.912592+00:00
Published At
2021-06-10T00:00:00+00:00
Record Updated At
2021-06-10
Results Posted At
2021-06-10
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["NOMID", "CINCA Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-06-10"
protocolSection.identificationModule.nctId
"NCT00770601"
protocolSection.identificationModule.officialTitle
"A Multi-Center, Open Label, 24-Month Treatment Study to Establish the Safety, Tolerability, Efficacy, Pharmacokinetics of Canakinumab (Anti-IL-1 Beta Antibody) in Patients With NOMID / CINCA Syndrome"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2021-06-10"

Study condition terms

  • NOMID (protocolSection.conditionsModule.conditions)
  • CINCA Syndrome (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.